

# **BIBLIOGRAFIA RECOMENDADA RM CARDÍACA**

## **LIVROS DE TEXTO**

### **Cardiovascular MR Manual**

Plein S, Greenwood J, Ridgway JP  
Springer, 2nd Edition 2015.

### **The EACVI Textbook of Cardiovascular Magnetic Resonance**

Lombardi M, Plein S, Petersen S, et al.  
Oxford University, 1st Edition 2018.

### **Basic Principles of Cardiovascular MRI: Physic and Imaging Technique**

Syed MA, Raman SV, Simonetti OP  
Springer, 1st Edition 2015.

### **Cardiovascular Magnetic Resonance Pocket Guide**

Herzog BA, Greenwood JP, Plein S  
Second Edition May 2017

## **DOCUMENTOS DE REVISÃO/ARTIGOS**

### **1. Física, Segurança e Devices**

#### **1.1. Física**

### **Cardiovascular magnetic resonance physics for clinicians: part I**

Ridgway JP.  
J Cardiovasc Magn Reson. 2010 Nov 30;12:71.

### **Cardiovascular magnetic resonance physics for clinicians: Part II**

Biglands JD, Radjenovic A, Ridgway JP.  
J Cardiovasc Magn Reson. 2012 Sep 20;14:66.

### **MR physics in practice: how to optimize acquisition quality and time for cardiac MR imaging.**

Saloner D, Liu J, Haraldsson H.  
Magn Reson Imaging Clin N Am. 2015 Feb;23(1):1-6.

### **Cardiovascular Magnetic Resonance Physics for Clinicians Pocket Guide**

Herzog BA, Greenwood JP, Plein S  
First Edition 2015

### **1.1.1. Artefactos**

#### **Cardiovascular magnetic resonance artefacts.**

Ferreira PF, Gatehouse PD, Mohiaddin RH, et al.  
J Cardiovasc Magn Reson. 2013 May 22;15(1):41.

#### **Optimizing cardiac MR imaging: practical remedies for artifacts.**

Saremi F, Grizzard JD, Kim RJ.  
Radiographics. 2008 Jul-Aug;28(4):1161-87.

#### **Differentiation of myocardial scar from potential pitfalls and artefacts in delayed enhancement MRI.**

Turkbey EB, Nacif MS, Noureldin RA, et al.  
Br J Radiol. 2012 Nov;85(1019):e1145-54.

## **1.2. Segurança e Devices**

#### **[http://www.mrisafety.com/TMDL\\_list.php](http://www.mrisafety.com/TMDL_list.php)**

Official web site of the Institute For Magnetic Resonance Safety, Education, And Research.

#### **CMR and CT of the Patient With Cardiac Devices: Safety, Efficacy, and Optimization Strategies.**

Symons R, Zimmerman SL, Bluemke DA.  
JACC Cardiovasc Imaging. 2019 May;12(5):890-903.

#### **Consensus document on magnetic resonance imaging in patients with cardiac implanted electronic devices.**

Almeida AG, António N, Saraiva C, et al.  
Rev Port Cardiol (Engl Ed). 2021 Jan;40(1):41-52.

#### **MR labeling information for implants and devices: explanation of terminology**

Shellock FG, Woods TO, Crues JV 3rd.  
Radiology. 2009 Oct;253(1):26-30.

#### **Guidance on gadolinium-based contrast agent administration to adult patients**

<https://www.rcr.ac.uk/publication/guidance-gadolinium-based-contrast-agent-administration-adult-patients>

## **2. Metodologia**

#### **Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update.**

Kramer, C.M., Barkhausen, J., Bucciarelli-Ducci, C. *et al.*  
J Cardiovasc Magn Reson **22**, 17 (2020).

**Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update.**

Schulz-Menger, J., Bluemke, D.A., Bremerich, J. *et al.*  
*J Cardiovasc Magn Reson* **22**, 19 (2020).

**SCMR guidelines for reporting cardiovascular magnetic resonance examinations.**

Hundley, W.G., Bluemke, D.A., Bogaert, J. *et al.*  
*J Cardiovasc Magn Reson* **24**, 29 (2022)

**30-minute CMR for common clinical indications: a Society for Cardiovascular Magnetic Resonance white paper.**

Raman, S.V., Markl, M., Patel, A.R. *et al.*  
*J Cardiovasc Magn Reson* **24**, 13 (2022).

## **2.1. Valores de referência**

**European Association of Cardiovascular Imaging expert consensus paper: a comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity.**

Petersen SE, Khanji MY, Plein S, et al.  
*Eur Heart J Cardiovasc Imaging*. 2019 Dec 1;20(12):1321-1331.

**Reference ranges ("normal values") for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update.**

Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, et al.  
*J Cardiovasc Magn Reson*. 2020 Dec 14;22(1):87.

## **2.2. Mappings, 4D Flow e feature-tracking**

**Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2\* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).**

Messroghli, D.R., Moon, J.C., Ferreira, V.M. *et al.*  
*J Cardiovasc Magn Reson* **19**, 75 (2017).

**T1 Mapping: Basic Techniques and Clinical Applications.**

Taylor AJ, Salerno M, Dharmakumar R, et al.  
*JACC Cardiovasc Imaging*. 2016 Jan;9(1):67-81.

**T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review.**

Haaf P, Garg P, Messroghli DR, et al.  
*J Cardiovasc Magn Reson*. 2016 Nov 30;18(1):89.

**T2 mapping in myocardial disease: a comprehensive review.**

O'Brien, A.T., Gil, K.E., Varghese, J. *et al.*  
*J Cardiovasc Magn Reson* **24**, 33 (2022).

#### **4D flow cardiovascular magnetic resonance consensus statement.**

Dyverfeldt P, Bissell M, Barker AJ, et al.  
J Cardiovasc Magn Reson. 2015 Aug 10;17(1):72.

#### **Clinical intra-cardiac 4D flow CMR: acquisition, analysis, and clinical applications.**

Demirkiran A, van Ooij P, Westenberg JJM, et al.  
Eur Heart J Cardiovasc Imaging. 2022 Jan 24;23(2):154-165.

#### **Cardiovascular Magnetic Resonance Myocardial Feature Tracking: Concepts and Clinical Applications.**

Schuster A, Hor KN, Kowallick JT, Beerbaum P, Kutty S.  
Circ Cardiovasc Imaging. 2016 Apr;9(4):e004077.

#### **Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use.**

Pedrizzetti G, Claus P, Kilner PJ, Nagel E.  
J Cardiovasc Magn Reson. 2016 Aug 26;18(1):51.

### **3. Indicações clínicas da RM Cardíaca**

#### **SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance.**

Leiner, T., Bogaert, J., Friedrich, M.G. *et al.*  
J Cardiovasc Magn Reson **22**, 76 (2020).

#### **Cardiovascular magnetic resonance: applications and practical considerations for the general cardiologist.**

Arnold JR, McCann GP.  
Heart. 2020 Feb;106(3):174-181.

### **4. Avaliação de Cardiopatia Isquêmica**

#### **4.1. Viabilidade e Realce tardio**

#### **Computed Tomography and Cardiac Magnetic Resonance in Ischemic Heart Disease.**

Dweck MR, Williams MC, Moss AJ, et al.  
J Am Coll Cardiol. 2016 Nov 15;68(20):2201-2216.

#### **Assessment of myocardial viability by cardiac MRI.**

Al-Sabeq B, Nabi F, Shah DJ.  
Curr Opin Cardiol. 2019 Sep;34(5):502-509.

#### **CMR for myocardial characterization in ischemic heart disease: state-of-the-art and future developments.**

Emrich, T., Halfmann, M., Schoepf, U.J. *et al.*  
Eur Radiol Exp **5**, 14 (2021).

**Multimodality imaging of myocardial viability: an expert consensus document from the European Association of Cardiovascular Imaging (EACVI).**

Almeida AG, Carpenter JP, Cameli M, et al.  
Eur Heart J Cardiovasc Imaging. 2021 Jul 20;22(8):e97-e125.

## **4.2. RM de stress**

**MR myocardial perfusion imaging.**

Coelho-Filho OR, Rickers C, Kwong RY, et al.  
Radiology. 2013 Mar;266(3):701-15.

**MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial.**

Schwitzer J, Wacker CM, van Rossum AC, et al.  
Eur Heart J. 2008 Feb;29(4):480-9.

**MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial.**

Schwitzer J, Wacker CM, Wilke N, et al.  
Eur Heart J. 2013 Mar;34(10):775-81.

**Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial.**

Greenwood JP, Maredia N, Younger JF, et al.  
Lancet. 2012 Feb 4;379(9814):453-60.

**Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging.**

Shaw LJ, Berman DS, Picard MH, et al. ISCHEMIA Trial Investigators.  
JACC Cardiovasc Imaging. 2014 Jun;7(6):593-604.

**Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease.**

Nagel E, Greenwood JP, McCann GP, et al. MR-INFORM Investigators.  
N Engl J Med. 2019 Jun 20;380(25):2418-2428.

**Value of Vasodilator Stress Cardiac Magnetic Resonance Imaging: A Multicenter Study With 48 000 Patient-Years of Follow-up.**

Heitner JF, Kim RJ, Kim HW, et al.  
JAMA Cardiol. 2019 Mar 1;4(3):256-264.

**How to do quantitative myocardial perfusion cardiovascular magnetic resonance.**

Sharrack N, Chiribiri A, Schwitzer J, Plein S.  
Eur Heart J Cardiovasc Imaging. 2022 Feb 22;23(3):315-318.

### **4.3. Avaliação de síndromes coronárias agudas**

**Use of cardiovascular magnetic resonance imaging in acute coronary syndromes.**

Lockie T, Nagel E, Redwood S, Plein S.

Circulation. 2009 Mar 31;119(12):1671-81.

**Cardiovascular Magnetic Resonance in Acute ST-Segment-Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions.**

Bulluck H, Dharmakumar R, Arai AE, et al.

Circulation. 2018 May 1;137(18):1949-1964.

### **4.4. Avaliação de doença microvascular**

**Diagnosis of Microvascular Angina Using Cardiac Magnetic Resonance.**

Liu A, Wijesurendra RS, Liu JM, et al.

J Am Coll Cardiol. 2018 Mar 6;71(9):969-979.

**High-Resolution Cardiac Magnetic Resonance Imaging Techniques for the Identification of Coronary Microvascular Dysfunction.**

Rahman H, Scannell CM, Demir OM, et al.

JACC Cardiovasc Imaging. 2021 May;14(5):978-986.

## **5. Avaliação de MINOCA, Miocardite e Takotsubo**

### **5.1. MINOCA**

**The Role of Cardiac Magnetic Resonance in Myocardial Infarction and Non-obstructive Coronary Arteries.**

Liang K, Nakou E, Del Buono MG, et al.

Front Cardiovasc Med. 2022 Jan 17;8:821067.

### **5.2. Miocardite**

**Multiparametric Cardiovascular Magnetic Resonance Approach in Diagnosing, Monitoring, and Prognostication of Myocarditis.**

Eichhorn C, Greulich S, Bucciarelli-Ducci C, et al.

JACC Cardiovasc Imaging. 2022 Jul;15(7):1325-1338.

**Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations.**

Ferreira VM, Schulz-Menger J, Holmvang G, et al.

J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176.

### 5.3. Takotsubo

**The role of cardiovascular magnetic resonance in takotsubo syndrome.**

Plácido, R., Cunha Lopes, B., Almeida, A.G. *et al.*

*J Cardiovasc Magn Reson* **18**, 68 (2017).

## 6. Avaliação de Miocardiopatias

**How to evaluate cardiomyopathies by cardiovascular magnetic resonance parametric mapping and late gadolinium enhancement.**

Menghoum N, Vos JL, Pouleur AC, Nijveldt R, Gerber BL.

*Eur Heart J Cardiovasc Imaging*. 2022 Apr 18;23(5):587-589.

**The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Highly Trained Athletes.**

Gati S, Sharma S, Pennell D.

*JACC Cardiovasc Imaging*. 2018 Feb;11(2 Pt 1):247-259.

**Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities.**

Quarta G, Gori M, Iorio A, *et al.*

*Eur J Heart Fail*. 2020 Jul;22(7):1065-1075.

### 6.1. Miocardiopatia Dilatada

**Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy.**

Patel AR, Kramer CM.

*JACC Cardiovasc Imaging*. 2017 Oct;10(10 Pt A):1180-1193.

**Emerging Techniques for Risk Stratification in Nonischemic Dilated Cardiomyopathy: JACC Review Topic of the Week.**

Marrow BA, Cook SA, Prasad SK, *et al.*

*J Am Coll Cardiol*. 2020 Mar 17;75(10):1196-1207.

**Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging.**

Donal E, Delgado V, Bucciarelli-Ducci C, Galli E, *et al.*

*Eur Heart J Cardiovasc Imaging*. 2019 Oct 1;20(10):1075-1093.

### 6.2. Miocardiopatia Arritmogénica

**The diagnostic performance of imaging methods in ARVC using the 2010 Task Force criteria.**

Borgquist R, Haugaa KH, Gilljam T, et al.  
Eur Heart J Cardiovasc Imaging. 2014 Nov;15(11):1219-25.

**Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update.**

te Riele AS, Tandri H, Bluemke DA.  
J Cardiovasc Magn Reson. 2014 Jul 20;16(1):50.

**Arrhythmogenic left ventricular cardiomyopathy.**

Corrado D, Basso C.  
Heart. 2022 May;108(9):733-743.

**Cardiac magnetic resonance imaging of arrhythmogenic cardiomyopathy: evolving diagnostic perspectives.**

Cipriani, A., Mattesi, G., Bariani, R. *et al.*  
*Eur Radiol* **33**, 270–282 (2023).

## **6.3. Miocardiopatia Hipertrófica**

**The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance.**

Noureldin RA, Liu S, Nacif MS, et al.  
J Cardiovasc Magn Reson. 2012 Feb 20;14(1):17.

**Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy.**

Maron MS.  
J Cardiovasc Magn Reson. 2012 Feb 1;14(1):13.

## **6.4. Doença de Fabry**

**Cardiac Magnetic Resonance in Fabry Disease: Morphological, Functional, and Tissue Features.**

Aquaro GD, De Gori C, Faggioni L, et al.  
Diagnostics (Basel). 2022 Nov 1;12(11):2652.

## **6.5. Miocardiopatia Infiltrativa**

**Trends in Diagnostic Imaging of Cardiac Amyloidosis: Emerging Knowledge and Concepts.**

Oda S, Kidoh M, Nagayama Y, et al.  
Radiographics. 2020 Jul-Aug;40(4):961-981.



### **Cardiovascular magnetic resonance in cardiac amyloidosis.**

Maceira AM, Joshi J, Prasad SK, et al.  
Circulation. 2005 Jan 18;111(2):186-93.

### **Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.**

Karamitsos TD, Piechnik SK, Banypersad SM, et al.  
JACC Cardiovasc Imaging. 2013 Apr;6(4):488-97.

### **Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis.**

Raina S, Lensing SY, Nairouz RS, et al.  
JACC Cardiovasc Imaging. 2016 Nov;9(11):1267-1277.

## **6.6. Miocardiopatia por sobrecarga de ferro**

### **Cardiovascular T2-star (T2\*) magnetic resonance for the early diagnosis of myocardial iron overload.**

Anderson LJ, Holden S, Davis B, et al.  
Eur Heart J. 2001 Dec;22(23):2171-9.

### **Improved survival of thalassaemia major in the UK and relation to T2\* cardiovascular magnetic resonance.**

Modell B, Khan M, Darlison M, et al.  
J Cardiovasc Magn Reson. 2008 Sep 25;10(1):42.

### **Cardiac T2\* magnetic resonance for prediction of cardiac complications in thalassaemia major.**

Kirk P, Roughton M, Porter JB, et al.  
Circulation. 2009 Nov 17;120(20):1961-8.

## **6.7. Miocardiopatia por excesso de trabeculações**

### **Excessive Trabeculation of the Left Ventricle: JACC: Cardiovascular Imaging Expert Panel Paper.**

Petersen SE, Jensen B, Aung N, et al.  
JACC Cardiovasc Imaging. 2023 Feb 6:S1936-878X(23)00031-1.

## **6.8. Miocardiopatia de Chagas**

### **Myocardial tissue characterization in Chagas' heart disease by cardiovascular magnetic resonance.**

Torreão JA, Ianni BM, Mady C, et al.  
J Cardiovasc Magn Reson. 2015 Nov 18;17:97.

## 6.9. Sarcoidose

### **Cardiac Sarcoidosis.**

Birnie DH, Nery PB, Ha AC, Beanlands RS.  
J Am Coll Cardiol. 2016 Jul 26;68(4):411-21.

### **Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis.**

Wand AL, Chrispin J, Saad E, et al.  
Front Cardiovasc Med. 2022 Jan 27;8:785279.

## 7. Doenças do Pericárdio

### **European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease.**

Cosyns B, Plein S, Nihoyanopoulos P, et al.  
Eur Heart J Cardiovasc Imaging. 2015 Jan;16(1):12-31.

### **Cardiovascular magnetic resonance in pericardial diseases.**

Bogaert, J., Francone, M.  
*J Cardiovasc Magn Reson* **11**, 14 (2009).

### **The contemporary role of cardiac computed tomography and cardiac magnetic resonance imaging in the diagnosis and management of pericardial diseases.**

Conte E, Agalbato C, Melotti E, et al.  
Can J Cardiol. 2023 Feb 3:S0828-282X(23)00076-4.

## 8. Avaliação de Doença Valvular

### **CMR in Evaluating Valvular Heart Disease: Diagnosis, Severity, and Outcomes.**

Myerson SG.  
JACC Cardiovasc Imaging. 2021 Oct;14(10):2020-2032.

### 8.1. Avaliação de lesões regurgitantes

### **Multi-modality imaging assessment of native valvular regurgitation: an EACVI and ESC council of valvular heart disease position paper.**

Lancellotti P, Pibarot P, Chambers J, et al.  
Eur Heart J Cardiovasc Imaging. 2022 Apr 18;23(5):e171-e232.

### **Use of Cardiac Magnetic Resonance Imaging in Assessing Mitral Regurgitation: Current Evidence.**

Uretsky S, Argulian E, Narula J, Wolff SD.  
J Am Coll Cardiol. 2018 Feb 6;71(5):547-563.

**Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging.**

Garg P, Swift AJ, Zhong L, et al.  
Nat Rev Cardiol. 2020 May;17(5):298-312.

## **8.2. Avaliação de estenose aórtica**

**Cardiac magnetic resonance imaging for the assessment of aortic stenosis.**

Singh A, McCann GP.  
Heart. 2019 Mar;105(6):489-497.

**Usefulness of Cardiac Magnetic Resonance Imaging in Aortic Stenosis.**

Bohbot Y, Renard C, Manrique A, et al.  
Circ Cardiovasc Imaging. 2020 May;13(5):e010356.

## **8.3. Avaliação pré-intervenção valvular**

**Cardiovascular Magnetic Resonance Imaging for Structural and Valvular Heart Disease Interventions.**

Cavalcante JL, Lalude OO, Schoenhagen P, et al.  
JACC Cardiovasc Interv. 2016 Mar 14;9(5):399-425.

## **9. Avaliação pré-intervenção electrofisiológica**

**Assessment of Left Atrial Fibrosis by Late Gadolinium Enhancement Magnetic Resonance Imaging: Methodology and Clinical Implications.**

Siebermair J, Kholmovski EG, Marrouche N.  
JACC Clin Electrophysiol. 2017 Aug;3(8):791-802.

**Use of Contemporary Imaging Techniques for Electrophysiological and Device Implantation Procedures.**

Auricchio A, Faletra FF.  
JACC Cardiovasc Imaging. 2020 Mar;13(3):851-865.

**Cardiac MRI and Fibrosis Quantification.**

Kholmovski EG, Morris AK, Chelu MG.  
Card Electrophysiol Clin. 2019 Sep;11(3):537-549.

**Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study.**

Marrouche NF, Wilber D, Hindricks G, et al.  
JAMA. 2014 Feb 5;311(5):498-506.

**Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial.**

Marrouche NF, Wazni O, McGann C, et al.  
JAMA. 2022 Jun 21;327(23):2296-2305.

## **10. Avaliação dos Grandes Vasos**

**Magnetic resonance angiography: current status and future directions.**

Hartung MP, Grist TM, François CJ.  
J Cardiovasc Magn Reson. 2011 Mar 9;13(1):19.

**The Role of Multimodality Imaging Approach in Acute Aortic Syndromes: Diagnosis, Complications, and Clinical Management.**

Perone, F, Guglielmo, M, Coceani, M, et al  
*Diagnostics*. 2023; 13(4):650.

## **11. Avaliação de Massas e Tumores**

**MR imaging of cardiac tumors and masses: a review of methods and clinical applications.**

Motwani M, Kidambi A, Herzog BA, et al.  
Radiology. 2013 Jul;268(1):26-43.

**Cardiovascular magnetic resonance of cardiac tumors and masses.**

Gatti M, D'Angelo T, Muscogiuri G, et al.  
World J Cardiol. 2021 Nov 26;13(11):628-649.

## **12. Avaliação de Cardiopatia Congênita do Adulto**

**Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the use of cardiovascular magnetic resonance in pediatric congenital and acquired heart disease.**

Fogel, M.A., Anwar, S., Broberg, C. *et al.*  
*J Cardiovasc Magn Reson* **24**, 37 (2022).

**SCMR expert consensus statement for cardiovascular magnetic resonance of acquired and non-structural pediatric heart disease.**

Dorfman, A.L., Geva, T., Samyn, M.M. *et al.*  
*J Cardiovasc Magn Reson* **24**, 44 (2022).

**Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology.**

Kilner PJ, Geva T, Kaemmerer H, et al.  
Eur Heart J. 2010 Apr;31(7):794-805.

**Indications for cardiovascular magnetic resonance in children with congenital and acquired heart disease: an expert consensus paper of the Imaging Working Group of the AEPC and the Cardiovascular Magnetic Resonance Section of the EACVI.**

Valsangiacomo Buechel ER, Grosse-Wortmann L, Fratz S, et al.  
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):281-97.

**Cardiovascular Magnetic Resonance Congenital Heart Disease Pocket Guide**

Herzog BA, Greenwood JP, Plein S  
First Edition 2014

## **13. Avaliação de achados extra-cardíacos**

**Extra-cardiac findings in cardiovascular magnetic resonance: what the imaging cardiologist needs to know.**

Rodrigues JC, Lyen SM, Loughborough W, et al.  
J Cardiovasc Magn Reson. 2016 May 9;18(1):26.

**Incidental extra-cardiac findings on clinical CMR.**

Irwin RB, Newton T, Peebles C, et al.  
Eur Heart J Cardiovasc Imaging. 2013 Feb;14(2):158-66.